What did this study find?
Patients aged thirty to eighty-six with chronic pain completed six electrodermal biofeedback sessions across three weeks. They reported significantly less perceived pain, and blood C-reactive protein concentrations fell significantly as well, suggesting a measurable inflammatory change alongside the symptom report. The study was small and included no blinded sham comparison.
What are the details of this record?
- Full citation
- Oschman JL, et al. Clinical validation of a non-invasive electrodermal biofeedback device useful for reducing chronic perceived pain and systemic inflammation. Integr Med (Encinitas). 2019;18(1):42-50.
- Journal
- Integrative Medicine
- Authors
- Oschman JL, et al.
- Study design
- Controlled clinical study
- Sample size and population
- Patients aged 30-86 with chronic pain
- Evidence grade
- Grade B on the BioReg grading scale
- Reported findings
- 6 sessions over 3 weeks showed significant reduction in perceived pain (p<0.05) and decrease in C-reactive protein concentrations (p<0.05), indicating both pain relief and reduced systemic inflammation.
- DOI
- No DOI recorded
- PubMed
- PMID 30805908
- Related categories
- Chronic Pain (category grade A-)
A positive PEMF study is not evidence for a specific device unless the signal parameters studied, frequency, intensity, waveform, and exposure duration, are reasonably comparable to what that device produces. Where this record does not list those parameters, the source report did not publish them. See the grading methodology. Library last reviewed 2026-08-27.